What is King Pharmaceuticals's all other lines — year 4?

King Pharmaceuticals (KG) reported all other lines — year 4 of 4.7% in Q4 2025.

What does all other lines — year 4 mean?

This metric represents the aggregate financial performance of non-core business segments or miscellaneous product lines during the fourth fiscal year. It captures revenue and operational results from activities that do not fall under the company's primary reporting segments. Monitoring this category helps investors identify the contribution of secondary business units to the overall corporate portfolio.

King Pharmaceuticals KG All other lines — Year 4

Other product segments

Commercial Auto Liability

18.2%—

General Liability

15.9%—

European Hospital Liability

13.7%—

International

-0.3%—

Similar metrics at other companies

SPNTOther — Year 4

7.6%0.0pp

UFCSPersonal — Year 4

2.2%+0.1pp

IMAXAll Other — Revenue

$1.67M-8.4%

SPNTOther — Year 10

0%—

SKWDMulti-line Solutions — Year 4

13.6%+1.2pp

BOHYear four

$1.33B—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearFour.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's all other lines — year 4.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's all other lines — year 4?: King Pharmaceuticals (KG) reported all other lines — year 4 of 4.7% in Q4 2025.
What does all other lines — year 4 mean?: This metric represents the aggregate financial performance of non-core business segments or miscellaneous product lines during the fourth fiscal year. It captures revenue and operational results from activities that do not fall under the company's primary reporting segments. Monitoring this category helps investors identify the contribution of secondary business units to the overall corporate portfolio.